2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.09

PP02.09 - Xuehan Gao

Pdf Summary

Lung adenocarcinoma metastasis to the thyroid gland is extremely rare, with an incidence of less than 0.1%. A retrospective study over 11 years at Peking Union Medical College Hospital (PUMCH) examined the clinicopathological features and outcomes of this type of metastasis. The study emphasizes that thyroid gland metastasis from lung adenocarcinoma is not only uncommon but also often misdiagnosed due to its rarity. Despite its rapid progression, the prognosis for patients can be significantly improved with early treatment and the application of targeted therapies.<br /><br />Researchers involved in this study include experts from the Department of Thoracic Surgery and the Department of General Surgery at PUMCH. They note specific immunohistochemical markers such as TTF-1, NapsinA, and PAX8 which are pivotal in diagnosing this condition. These markers also help in distinguishing lung adenocarcinoma metastasis to the thyroid from other possible thyroid gland pathologies.<br /><br />Overall, while lung adenocarcinoma metastasis to the thyroid is highly unusual, awareness and prompt diagnosis can lead to better management strategies and outcomes. The study underscores the importance of considering this rare form of metastasis in differential diagnoses, especially in patients with a history of lung adenocarcinoma presenting with thyroid abnormalities. The findings advocate for further research and reinforced clinical awareness to avoid misdiagnosis and to facilitate timely therapeutic interventions.

Keywords

lung adenocarcinoma

thyroid gland metastasis

Peking Union Medical College Hospital

clinicopathological features

immunohistochemical markers

TTF-1

NapsinA

PAX8

targeted therapies

misdiagnosis